Login
Companies $IONS
$28.02 +$0.01 (0.04%) After hours
IONIS PHARMACEUTICALS INC logo

IONIS PHARMACEUTICALS INC

ionis.com

What Do They Do?

Develops and sells medicines for serious diseases, including neurological and cardiometabolic conditions.

How Do They Make Money?

The largest source is partner-funded research and collaboration activity: partners pay as Ionis performs research, when licenses are delivered and when certain milestones are achieved; medicine sales and royalties from partner sales also contribute.

revenue
SegmentShareRevenue
Product Sales, Net
Sold outright

12%
FY2022: 5.1%
Royalty Revenue
Licensed

30%
Other Commercial Revenue
3.7%
FY2022: 10%
Commercial Revenue
46%
FY2022: 52%
Collaborative Agreement Revenue
Mix

49%
FY2022: 35%
WAINUA Joint Development Revenue
Recurring
4.5%
FY2022: 13%
Research and Development Revenue
Mix

54%
FY2022: 48%

Who Are Their Customers?

Ionis sells TRYNGOLZA and DAWNZERA itself in the U.S.; AstraZeneca and Biogen commercialize WAINUA and SPINRAZA, while Sobi distributes WAYLIVRA in Europe and PTC commercializes it in Brazil. Development partners license Ionis technology and work with it on research.

Do Revenues Turn Into Profits?

No. It lost $381.4M in FY2025.

Operating income, FY2025
−40% of revenue
▲ +20% (Loss) vs FY2024 (−$475.1M, −67%)
Net income, FY2025
−40% of revenue
▲ +16% (Loss) vs FY2024 (−$453.9M, −64%)
Free cash flow, FY2025
−34% of revenue
▲ +41% (Loss) vs FY2024 (−$546.2M, −77%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +55%
vs $156.7M in Q3 FY2025
Net income
▲ +14% (Loss)
vs −$128.6M in Q3 FY2025
Research and Development Revenue share of revenue vs 26.2% in Q3 FY2025
  • Nov 9, 2026 TRYNGOLZA product sales guidance lowered Ionis cited a slower launch ramp while reaffirming its total revenue, operating loss and cash guidance.
  • Oct 20, 2026 Partner GSK's hepatitis B medicine received U.S. approval Ionis licensed bepirovirsen to GSK and may receive additional regulatory and sales milestones and royalties.
  • Sep 3, 2026 FDA approved ZANVASTRO for Alexander disease The approval marked a new Ionis-run product launch; Recordati holds rights outside the U.S.

Growing. Revenue grew 16% in 4 years, from $810.5M in FY2021 to $943.7M in FY2025, about 4% a year.

More marketed medicines and direct launches The older report described SPINRAZA, TEGSEDI and WAYLIVRA as marketed, with eplontersen and tofersen still in development; the latest describes additional marketed medicines and independent Ionis sales of TRYNGOLZA and DAWNZERA alongside partner-led commercialization.

Revenue over time
Product Sales, Net Royalty Revenue Other Commercial Revenue Commercial Revenue Collaborative Agreement Revenue WAINUA Joint Development Revenue Research and Development Revenue SPINRAZA Royalties Licensing and Other Royalties Other Revenue WAINUA Royalties DAWNZERA Sales Other Royalties TRYNGOLZA Sales
$1B$500M$0

Who Do They Compete With?

Competes with Arrowhead Pharmaceuticals, Roche, NorthSea Therapeutics, Eli Lilly, Takeda, BioCryst, CSL Behring, Pharvaris, Intellia, ADARx, Alnylam, Pfizer, BridgeBio, Novo Nordisk, Novartis, Ultragenyx, Neuren, Gilead Sciences, Arbutus Biopharma, and Barinthus Bio

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support